i-SENS, Inc.
Financials
Valuation Metrics
i-SENS, Inc.'s Market Cap is ₩4974B. At end of 2025 it was ₩4702B. Ranked #444 of 2,405 in KR market (top 18%), #159 of 1,627 on KOSDAQ (top 10%), #11 of 94 in Health Care Equipment & Services (top 12%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 497.43B KRW | KR#444/2,405 Sec#11/94 |
| Revenue | 326.19B KRW | KR#796/2,405 Sec#8/94 |
| Net Income | -4.11B KRW | KR—/2,405 Sec—/94 |
| Total Assets | 599.15B KRW | KR#685/2,405 Sec#9/94 |
| Net Assets | 363.98B KRW | KR#640/2,405 Sec#9/94 |
| Employees | 904 | KR#280/2,405 Sec#2/94 |
| Value | ||
| P/B | 1.37x | KR#1,763/2,405 Sec#56/94 |
| P/S | 1.52x | KR#1,704/2,405 Sec#43/94 |
| EV/EBITDA | 57.45x | KR#1,390/2,405 Sec#44/94 |
| FCF Yield | -1.53% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | -1.13% | KR#1,629/2,405 Sec#53/94 |
| ROA | -0.69% | KR#1,633/2,405 Sec#55/94 |
| Op. Margin | 3.22% | KR#1,212/2,405 Sec#45/94 |
| Revenue Growth | 6.64% | KR#1,092/2,405 Sec#60/94 |
| Earnings Growth | -550.90% | KR#1,301/2,405 Sec#47/94 |
| Financial Health | ||
| Debt Ratio | 64.61% | KR#1,147/2,405 Sec#65/94 |
| Total Debt | 165.33B KRW | KR#571/2,405 Sec#7/94 |
| FCF | -7.60B KRW | KR#1,612/2,405 Sec#58/94 |
| Cash | 58.64B KRW | KR#674/2,405 Sec#15/94 |
| Current Ratio | 1.76x | KR#992/2,405 Sec#59/94 |
| Net Debt/EBITDA | 10.15x | KR#1,227/2,405 Sec#41/94 |
| Dividend | ||
| Div. Yield | 0.59% | KR#1,249/2,405 Sec#38/94 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/94 |
| Performance | ||
| 1Y Return | -2.77% | KR#591/2,405 Sec#15/94 |
| 1M Return | 0.18% | KR#318/2,405 Sec#10/94 |
| From 52W High | -39.06% | KR#716/2,405 Sec#26/94 |
| 1Y MDD | -45.59% | KR#762/2,405 Sec#27/94 |
| Trading | ||
| Volume | 45,864 shares | KR#1,027/2,405 Sec#37/94 |
| Trading Value | 763.7M KRW | KR#662/2,405 Sec#16/94 |
| Foreign Own. | 24.84% | KR#167/2,405 Sec#4/94 |
| Per Share | ||
| EPS | -139 KRW | KR—/2,405 Sec—/94 |
| BPS | 12,308 KRW | KR#836/2,405 Sec#16/94 |
Company Info
Established in 2000, this company develops, manufactures, and sells medical sensors and measuring instruments using electrochemical and biosensor technologies. Its blood glucose meter segment, including self-monitoring and continuous glucose monitoring systems, accounts for over 80% of sales, while the point-of-care testing (POCT) segment for critical care analysis equipment contributes 10%. The company holds world-leading technology for blood sample volume (0.5㎕) and measurement speed (5 seconds), expanding global market share with the domestic launch of CareSens Air, the first continuous glucose monitoring system in Korea. i-SENS is headquartered in Seocho-gu, Seoul.